Citations

Mayo Clinic

Showing 10 of 108551 citations.

Incidence and clinical outcomes of perforations during mechanical thrombectomy for medium vessel occlusion in acute ischemic stroke: A retrospective, multicenter, and multinational study
Musmar, Basel , Salim, Hamza , Kobeissi, Hassan , Shaikh, Hamza , Khalife, Jane , Abdalkader, Mohamad , Klein, Piers , Heit, Jeremy J. , Regenhardt, Robert W. , Cancelliere, Nicole M , Amllay, Abdelaziz , Dusart, Anne , Bellante, Flavio, Rouchaud, Aymeric , Puri, Ajit S , Dyzmann, Christian , Kan, Peter , Colasurdo, Marco , Berge, Jérôme , Barreau, Xavier , Nedelcu, Simona , Henninger, Nils , Marotta, Thomas R. , Stapleton, Christopher J. , Rabinov, James D. , Dofuku, Shogo , Tan, Benjamin Yong‐Qiang , Salazar‐Marioni, Sergio , Capirossi, Carolina , Chervak, Lina , Adeeb, Nimer , Tjoumakaris, Stavropoula , Khandelwal, Priyank , Biswas, Arundhati , Clarençon, Frédéric , Elhorany, Mahmoud , Premat, Kévin , Valente, Iacopo , Filipe, João Pedro , Varela, Ricardo , Quintero‐Consuegra, Miguel , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Yedavalli, Vivek , Aziz, Yasmin , Stracke, Christian Paul , Kadirvel, Ramanathan , Hsieh, Cheng‐Yang , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Musmar, Basel , Salim, Hamza , Kobeissi, Hassan , Klein, Piers , Nguyen, Thanh N , Regenhardt, Robert W , Bellante, Flavio , Forestier, Géraud , Marnat, Gaultier , Ota, Takahiro , Dofuku, Shogo , Yeo, Leonard Ll , Salazar-Marioni, Sergio , Jabbour, Pascal , Gonzalez, Nestor R , Möhlenbruch, Markus A , Jesser, Jessica , Aziz, Yasmin , Alexandru Radu, Răzvan , Faizy, Tobias D , Fahed, Robert , Liebeskind, David S. , Heit, Jeremy J , Yedavalli, Vivek S , Cancelliere, Nicole M , Rouchaud, Aymeric , Colasurdo, Marco , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Dmytriw, Adam A. , Ghozy, Sherief , Siegler, James E. , Nguyen, Thanh N. , Bernstock, Joshua D. , Naamani, Kareem El , Meyer, Lukas , Forestier, Géraud , Saleme, Suzana , Mounayer, Charbel , Fiehler, Jens , Kühn, Anna Luisa , Sibon, Igor , Gopinathan, Anil , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Renieri, Leonardo , Mowla, Ashkan , Vagal, Achala , Cuellar, Hugo , Jabbour, Pascal , Khandelwal, Priyank , Pedicelli, Alessandro , Schiphorst, Adrien ter , Harker, Pablo , Gory, Benjamin , Hecker, Constantin , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Thomas, Ajith J , Radu, Răzvan Alexandru , Fahed, Robert , Weyland, Charlotte S. , Mendes Pereira, Vitor

European Stroke Journal | February 27, 2024 | Volume: 9 | Issue: 2 | Pages: 328-337

10.1177/23969873231219412 | PMID 38409796 Get It

Abstract Background: Mechanical thrombectomy (MT) has revolutionized the treatment of acute ischemic stroke (AIS) due to large vessel occlusion (LVO), but its efficacy and safety in medium vessel occlusion (MeVO) remain less explored. This multicenter, retrospective study aims to investigate the incidence and clinical outcomes of vessel perforations (confirmed by extravasation during an angiographic series) during MT for AIS caused by MeVO. Methods: Data were collected from 37 academic centers across North America, Asia, and Europe between September 2017 and July 2021. A total of 1373 AIS patients with MeVO underwent MT. Baseline characteristics, procedural details, and clinical outcomes were analyzed. Results: The incidence of vessel perforation was 4.8% (66/1373). Notably, our analysis indicates variations in perforation rates across different arterial segments: 8.9% in M3 segments, 4.3% in M2 segments, and 8.3% in A2 segments (p = 0.612). Patients with perforation had significantly worse outcomes, with lower rates of favorable angiographic outcomes (TICI 2c-3: 23% vs 58.9%, p < 0.001; TICI 2b-3: 56.5% vs 88.3%, p < 0.001). Functional outcomes were also worse in the perforation group (mRS 0–1 at 3 months: 22.7% vs 36.6%, p = 0.031; mRS 0–2 at 3 months: 28.8% vs 53.9%, p < 0.001). Mortality was higher in the perforation group (30.3% vs 16.8%, p = 0.008). Conclusion: This study reveals that while the occurrence of vessel perforation in MT for AIS due to MeVO is relatively rare, it is associated with poor functional outcomes and higher mortality. The findings highlight the need for increased caution and specialized training in performing MT for MeVO. Further prospective research is required for risk mitigation strategies.
Antidepressant Effects of Aerobic Exercise After Spinal Cord injury
Mercier, Hannah W. , Picard, Glen, Solinsky, Ryan , Solinsky, Ryan , Linnman, Clas , Taylor, Andrew J.

No container title available | February 27, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3875889/v1 Get It

Abstract Study Design: Secondary outcome measures analysis of a randomized, controlled study. Objectives: To assess the effects of hybrid-functional electrical stimulation (FES) rowing, arms only (AO) rowing and waitlist (WL) controls on pain, pain interference, and depression in individuals with spinal cord injury (SCI). Setting: Outpatient rehabilitation networks Methods: 44 participants were randomly assigned to FES (n = 19), AO (n= 12) or WL (n=13). The FES group completed 6 months of rowing scheduled 3 times per week. Individuals in the AO and WL groups were allowed to cross over to FES rowing after 6 months and were included in subsequent analyses of the effects of FES rowing. Rowing distance and intensity was logged, and maximal oxygen consumption (VO2max) measures were obtained before and after the intervention. Changes in the Patient-Reported Outcomes Measurement Information System (PROMIS-56) derived pain interference, pain, and depression scores were analyzed. Results: FES-rowing led to modest improvements in depression, AO led to modest improvements in pain intensity, and WL did not improve pain nor depression. After incorporating individuals who crossed over to FES rowing, we observed modest but significant improvement in depression scores but not in pain. Among the participants who benefited from the FES intervention, the reduction in depression was correlated to the average weekly rowing distance (r2=0.79 p=0.0001). Conclusions: 6 months of FES rowing spent in a supportive environment can help persons with spinal cord injuries alleviate moderate depression in a dose-dependent manner.
Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma
Truong, Huong L. , Barreto, Jason N. , Mara, Kristin C. , Hampel, Paul J. , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Thanarajasingam, Gita , Thompson, Carrie A. , Wang, Yucai , Witzig, Thomas E. , Witzig, T.E. , Herrmann, Sandra M , Leung, Nelson , Wang, Yucai , Mara, Kristin C , Micallef, Ivana N , Herrmann, Sandra M. , Leung, Nelson

JCO Oncology Practice | February 26, 2024 | Volume: 20 | Issue: 6 | Pages: 797-807

10.1200/op.23.00628 | PMID 38408299 Get It

PURPOSE Limited evidence exists regarding methotrexate (MTX) resumption after patients with lymphoma receive glucarpidase for toxic MTX levels and acute kidney injury (AKI). METHODS This retrospective review included adults with lymphoma treated with glucarpidase after MTX at Mayo Clinic between January 31, 2020, and October 10, 2022. Descriptive statistics summarize patient characteristics and clinical outcomes. RESULTS Of 11 patients treated with glucarpidase after MTX, seven (64%) were rechallenged with MTX. Indications for MTX rechallenge included confirmed CNS disease (n = 6, 86%) and intravascular lymphoma (n = 1, 14%). Compared with the nonrechallenged subgroup, before receiving MTX that required glucarpidase rescue, the rechallenged patients had lower median pretreatment serum creatinine (Scr; 0.7 v 1.2 mg/dL), and none had AKI with previous MTX doses, n = 0 (0%) versus n = 2 (50%). During the MTX dose requiring glucarpidase rescue, the rechallenged group had lower median peak Scr (1.26 v 3.32 mg/dL) and lower incidence of AKI stage III (n = 1 [14%] v n = 3 [75%]), and none of the rechallenged patients required renal replacement therapy (RRT; n = 0 [0%] v n = 1 [25%]). At the first rechallenge after glucarpidase administration, the median MTX dose reduction was 56% (range, 46%-75%), and the lowest used dose when prescribed according to each treatment protocol schedule was 1.5 g/m2. Two (29%) patients experienced AKI (n = 1 stage I, n = 1 stage II) after MTX rechallenge. Zero patients required RRT, and zero required another glucarpidase administration. Six (86%) patients completed all recommended MTX doses. CONCLUSION In selected adults with lymphoma who required glucarpidase for toxic MTX levels after administration of high-dose MTX, resumption of MTX therapy at lower doses is safe. Patients selected for MTX resumption had experienced less severe AKI during the previous cycle compared with those not selected for MTX resumption.
Thalidomide’s Role in Recurrent Bleeding Due to Small-intestinal Angiodysplasia
Harris, Zoey I., Shah, Surbhi

The Hematologist | February 26, 2024 | Volume: 21 | Issue: 2 | Pages: No page available

10.1182/hem.v21.2.202422 Get It

PerspectiveBeing “The Only”: My Experience as a Black Hematologist
Warsame, Rahma

The Hematologist | February 26, 2024 | Volume: 21 | Issue: 2 | Pages: No page available

10.1182/hem.v21.2.2024212 Get It

Myocarditis: Entering the Mainstream
Cooper, Leslie T.

Circulation | February 26, 2024 | Volume: 149 | Issue: 9 | Pages: 639-640

10.1161/circulationaha.123.065484 | PMID 38408144 Get It

Patient Sex in Prescribing CGRP Receptor Antagonists for Migraine—Reply
Porreca, Frank , Dodick, David W.

JAMA Neurology | February 26, 2024 | Volume: 81 | Issue: 4 | Pages: 424

10.1001/jamaneurol.2023.5838 | PMID 38407903 Get It

Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab
Vazirnia, Donna , Verduzco, Alejandro Del Rio , Soefje, Scott A. , Sanders, Kristyn A., Sandahl, Tyler B. , Del Rio Verduzco, Alejandro , Soefje, Scott A , Sandahl, Tyler B

JCO Oncology Practice | February 26, 2024 | Volume: 22 | Issue: 6 | Pages: 1049-1055

10.1200/op.23.00470 | PMID 38408288 Get It

PURPOSE Daratumumab is an anti-CD38 monoclonal antibody used to treat multiple myeloma and light chain amyloidosis. Because daratumumab may cause reactions after intravenous or subcutaneous (SC) administration, the manufacturer labeling recommends administration of premedications before every dose. Given incidence of infusion reactions appears to be rare after cycle 1, in April 2022, the Mayo Clinic implemented a practice change in which premedications were omitted from all daratumumab order sets after completion of cycle 1. This study investigated the safety of this practice. METHODS A retrospective chart review at the Mayo Clinic reviewed eligible patients with multiple myeloma or amyloid light-chain (AL) amyloidosis who received their first dose of daratumumab within the 4 months preceding the date of implementation (preimplementation group) or no more than 4 months after (postimplementation group) the date of implementation on April 13, 2022. Data were collected only from the first eight once per week doses of daratumumab. The primary outcome was the incidence of infusion-related reactions. Data analyzed used descriptive statistics. RESULTS Nearly all patients (95.9%) received daratumumab by SC route of administration. Of the 97 patients in the preimplementation group, >90% received premedications throughout cycles 1 and 2, and five patients (5.2%) experienced infusion reactions. Of 72 patients in the postimplementation group, <20% received premedications during cycle 2 and three patients (4.2%) experienced infusion reactions. All infusion reactions occurred within the first daratumumab cycle, indicating elimination of cycle 2 premedications did not cause any infusion reactions. No patient experienced more than one infusion reaction. CONCLUSION Omission of premedications after cycle 1 of daratumumab did not increase the incidence of infusion. Premedications may safely be omitted after cycle 1 of daratumumab when administered by the SC route.
Toward Equitable Kidney Function Estimation in Critical Care Practice: Guidance From the Society of Critical Care Medicine’s Diversity, Equity, and Inclusion in Renal Clinical Practice Task Force
Frazee, Erin N. , McNett, Molly , Sakhuja, Ankit , Andrews, Adair, Miano, Todd A. , Martin, Niels Douglas , Basu, Rajit K. , Ablordeppey, Enyo

Critical Care Medicine | February 26, 2024 | Volume: 52 | Issue: 6 | Pages: 951-962

10.1097/ccm.0000000000006237 | PMID 38407240 Get It

OBJECTIVES: Accurate glomerular filtration rate (GFR) assessment is essential in critically ill patients. GFR is often estimated using creatinine-based equations, which require surrogates for muscle mass such as age and sex. Race has also been included in GFR equations, based on the assumption that Black individuals have genetically determined higher muscle mass. However, race-based GFR estimation has been questioned with the recognition that race is a poor surrogate for genetic ancestry, and racial health disparities are driven largely by socioeconomic factors. The American Society of Nephrology and the National Kidney Foundation (ASN/NKF) recommend widespread adoption of new “race-free” creatinine equations, and increased use of cystatin C as a race-agnostic GFR biomarker. DATA SOURCES: Literature review and expert consensus. STUDY SELECTION: English language publications evaluating GFR assessment and racial disparities. DATA EXTRACTION: We provide an overview of the ASN/NKF recommendations. We then apply an Implementation science methodology to identify facilitators and barriers to implementation of the ASN/NKF recommendations into critical care settings and identify evidence-based implementation strategies. Last, we highlight research priorities for advancing GFR estimation in critically ill patients. DATA SYNTHESIS: Implementation of the new creatinine-based GFR equation is facilitated by low cost and relative ease of incorporation into electronic health records. The key barrier to implementation is a lack of direct evidence in critically ill patients. Additional barriers to implementing cystatin C-based GFR estimation include higher cost and lack of test availability in most laboratories. Further, cystatin C concentrations are influenced by inflammation, which complicates interpretation. CONCLUSIONS: The lack of direct evidence in critically ill patients is a key barrier to broad implementation of newly developed “race-free” GFR equations. Additional research evaluating GFR equations in critically ill patients and novel approaches to dynamic kidney function estimation is required to advance equitable GFR assessment in this vulnerable population.
REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer
Boggi, Ugo , Kauffmann, Emanuele F. , Barreto, Savio George , Fusai, Giuseppe , Hackert, Thilo , Hilal, Mohammad Abu , Shrikhande, Shailesh, Truty, Mark J. , Werner, Jens , Wolfgang, Christopher L. , Capretti, Giovanni , Cattelani, Alice , Sio, Davide De , Dato, Armando Di, Meo, Giovanna Di , Gianfaldoni, Cesare , Salinas, C , Montorsi, Roberto Maria , Pagnanelli, Michele , Poli, Andrea , Sucameli, Francesco , Viti, Virginia, Addeo, Pietro , Bachellier, Philippe , Barbarello, Linda, Busquets, Juli , Butturini, Giovanni , Caniglia, Fabio, Chunhua, Xi, Colangelo, Ettore, Coratti, Andrea , Costa, Francesca, Crafa, Francesco , Valle, Raffaele Dalla , Carlis, Luciano De , Chiaro, Marco Del , Domak, Safi, Ercolani, Giorgio , Filauro, Marco, Gruttaduaria, Salvatore, Izbicki, Jakob R. , Jovine, Elio , Kiguchi, Gozo , Kooby, David A. , Lang, Hauke , Lombardo, Carlo , Massani, Marco , Miao, Yi , Mishima, Kohei , Molino, Carlo , Nardo, Bruno , Panaro, Fabrizio , Pasquali, Claudio , Perrone, Vittorio, Rangelova, Elena , Liu, Rong, Romito, Raffaele, Rosso, Edoardo , Schulick, Richard D. , Spampinato, Marcello , Troisi, Roberto , Uzunoglo, Faik G, Veneroni, Luigi , Zerbi, Alessandro , Vicente, Emilio, Vistoli, Fabio , Wakabayashi, Go , Zanus, Giacomo , Zureikat, Amer H., Zyromski, Nicholas J. , Davide, José , Dervenis, Christos, Konlon, Kevin C., Michelassi, Fabrizio, Nealon, William H. , Portolani, Nazario , Silva, Donzília Sousa , Ferrari, Viviana Nicoleta, Cameron, John L., Clavien, Pierre‐Alain , Asbun, Horacio J. , Board, The REDISCOVER Multidisciplinary Advisory, Truty, Mark, Napoli, Niccolò , Besselink, Marc G , Marchegiani, Giovanni , Salvia, Roberto , Bannone, Elisa , Coppola, Alessandro , Cucchetti, Alessandro , Fiorillo, Claudio , Ginesini, Michael , Lai, Quirino , Miccoli, Mario , Ricci, Claudio , Tamburrino, Domenico , Alfieri, Sergio , Baiocchi, Gian Luca , Balzano, Gianpaolo , Brolese, Alberto , Caputo, Damiano D. , Casadei, Riccardo , Wilde, Roeland F. de , Benedetto, Fabrizio Di , Sebastiano, Pierluigi Di , Hogg, Melissa E. , Egorov, V. , Ettorre, Giuseppe M , Falconi, Massimo , Ferrari, Giovanni , Ferrero, Alessandro , Giardino, Alessandro , Grazi, Gian Luca , Gruttadauria, Salvatore , Katz, Matthew H. G. , Keck, Tobias , Khatkov, Igor , Malleo, Giuseppe , Mazzaferro, Vincenzo , Memeo, Riccardo , Nagakawa, Yuichi , Nakamura, Masafumi , Liu, Rong, Romagnoli, Renato , Siriwardena, Ajith K. , Strobel, Oliver , Testini, Mario , Valente, Umberto , Vivarelli, Marco , Coppola, Roberto , D’Andrea, Vito , Frigerio, Isabella M. , Montorsi, Marco , Bozzi, Giuseppe, Ferrari, Viviana, Trivella, Maria Giovanna , Board, The REDISCOVER Multidisciplinary Advisory

Annals of Surgery | February 26, 2024 | Volume: 280 | Issue: 1 | Pages: 56-65

10.1097/sla.0000000000006248 | PMID 38407228 Get It

Objective: The REDISCOVER consensus conference aimed at developing and validating guidelines on the perioperative care of patients with borderline-resectable (BR-) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). Background: Coupled with improvements in chemotherapy and radiation, the contemporary approach to pancreatic surgery supports the resection of BR-PDAC and, to a lesser extent, LA-PDAC. Guidelines outlining the selection and perioperative care for these patients are lacking. Methods: The Scottish Intercollegiate Guidelines Network (SIGN) methodology was used to develop the REDISCOVER guidelines and create recommendations. The Delphi approach was used to reach a consensus (agreement ≥80%) among experts. Recommendations were approved after a debate and vote among international experts in pancreatic surgery and pancreatic cancer management. A Validation Committee used the AGREE II-GRS tool to assess the methodological quality of the guidelines. Moreover, an independent multidisciplinary advisory group revised the statements to ensure adherence to nonsurgical guidelines. Results: Overall, 34 recommendations were created targeting centralization, training, staging, patient selection for surgery, possibility of surgery in uncommon scenarios, timing of surgery, avoidance of vascular reconstruction, details of vascular resection/reconstruction, arterial divestment, frozen section histology of perivascular tissue, extent of lymphadenectomy, anticoagulation prophylaxis, and role of minimally invasive surgery. The level of evidence was however low for 29 of 34 clinical questions. Participants agreed that the most conducive means to promptly advance our understanding in this field is to establish an international registry addressing this patient population (https://rediscover.unipi.it/). Conclusions: The REDISCOVER guidelines provide clinical recommendations pertaining to pancreatectomy with vascular resection for patients with BR-PDAC and LA-PDAC, and serve as the basis of a new international registry for this patient population.